TY  - JOUR
AB  - Sex is a major determinant of cardiometabolic risk. DNA methylation (DNAm), an important epigenetic mechanism that differs between sexes, has been associated with cardiometabolic diseases. Therefore, we aimed to systematically review studies in adults investigating sex-specific associations of DNAm with intermediate cardiometabolic traits and incident cardiovascular disease including stroke, myocardial infarction (MI) and coronary heart disease (CHD). Five bibliographic databases were searched from inception to 15 July 2019. We selected 35 articles (based on 30 unique studies) from 17,023 references identified, with a total of 14,020 participants of European, North American or Asian ancestry. Four studies reported sex differences between global DNAm and blood lipid levels and stroke risk. In 25 studies that took a genome wide or candidate gene approach, DNAm at 31 gene sites was associated with sex differences in cardiometabolic diseases. The identified genes were PLA2G7, BCL11A, KDM6A, LIPC, ABCG1, PLTP, CETP, ADD1, CNN1B, HOOK2, GFBP-7,PTPN1, GCK, PTX3, ABCG1, GALNT2, CDKN2B, APOE, CTH, GNASAS, INS, PON1, TCN2, CBS, AMT, KDMA6A, FTO, MAP3K13, CCDC8, MMP-2 and ER-a. Prioritized pathway connectivity analysis associated these genes with biological pathways such as vitamin B12 metabolism, statin pathway, plasma lipoprotein, plasma lipoprotein assembly, remodeling and clearance and cholesterol metabolism. Our findings suggest that DNAm might be a promising molecular strategy for understanding sex differences in the pathophysiology of cardiometabolic diseases and that future studies should investigate the effects of sex on epigenetic mechanisms in cardiometabolic risk. In addition, we emphasize the gap between the translational potential and the clinical utilization of cardiometabolic epigenetics.
AU  - Asllanaj, E.*
AU  - Zhang, X.*
AU  - Ochoa Rosales, C.*
AU  - Nano, J.
AU  - Bramer, W.M.*
AU  - Portilla-Fernandez, E.*
AU  - Braun, K.V.E.*
AU  - Gonzalez-Jaramillo, V.*
AU  - Ahrens, W.*
AU  - Ikram, A.*
AU  - Ghanbari, M.*
AU  - Voortman, T.*
AU  - Franco, O.H.*
AU  - Muka, T.*
AU  - Glisic, M.*
C1  - 58497
C2  - 48138
CY  - Elsevier House, Brookvale Plaza, East Park Shannon, Co, Clare, 00000, Ireland
SP  - 6-26
TI  - Sexually dimorphic DNA-methylation in cardiometabolic health: A systematic review.
JO  - Maturitas
VL  - 135
PB  - Elsevier Ireland Ltd
PY  - 2020
SN  - 0378-5122
ER  - 

TY  - JOUR
AB  - Objective: To determine regional variations in the prevalence and applied therapy regimes of current menopausal hormone therapy (HT) in Germany. Methods: Three population-based surveys, analysing data of 45-74 years old women, were compared: The Study of Health in Pomerania (SHIP; 1123 participants; northeast Germany, October 1997-May 2001), Cooperative Health Research in the Augsburg Region Survey 2000 (KORA; 1253 participants; south Germany, October 1999-April 2001) and Heinz Nixdorf Recall Study (HNR; 2257 participants; west Germany, December 2000-August 2003). A standardized interview technique provided data on current medication. Results: rhe age-standardized prevalence of HT was 17.0% (95% confidence interval (Cl): 14.9-19.1) in SHIP, 25.9% (95% CI: 23.6-28.3) in KORA and 24.7% (95% CI: 22.9-26.4) in HNR. Mean average time of intake of HT was 5.1 (SHIP), 7.5 (KORA) and 10.1 years (HNR). The use of estrogen plus progestogen combinations was equally common in all three surveys with proportions of about 15%, the use of unopposed estrogen in KORA and HNR was twice as high as in SHIP. In all three surveys oral estradiol was taken most often. Transdermal estradiol was preferred by KORA women whereas conjugated estrogens were taken most frequently by HNR women. Conclusions: Compared to northeast Germany HT was more often applied in the south and west of Germany. HT as long-term therapy was more common in West than in East Germany. In each study region there was a specific pattern of used HT components.
AU  - Heier, M.
AU  - Moebus, S.*
AU  - Meisinger, C.
AU  - Jöckel, K.-H.*
AU  - Völzke, H.*
AU  - Döring, A.
AU  - Alte, D.*
C1  - 864
C2  - 26224
SP  - 9-15
TI  - Menopausal hormone therapy in Germany. Results of three national surveys from 1997 to 2003.
JO  - Maturitas
VL  - 62
IS  - 1
PB  - Elsevier Ireland Ltd
PY  - 2009
SN  - 0378-5122
ER  - 

TY  - JOUR
AU  - Mueller, J.E.
AU  - Döring, A.
AU  - Heier, M.
AU  - Löwel, H.
C1  - 22055
C2  - 20682
SP  - 95-104
TI  - Prevalence and determinants of hormone replacement therapy in German woman 1984-1995.
JO  - Maturitas
VL  - 43
PY  - 2002
SN  - 0378-5122
ER  - 

TY  - JOUR
AU  - Seifert-Klauss, V.*
AU  - Mueller, J.E.
AU  - Luppa, P.*
AU  - Probst, R.*
AU  - Wilker, J.*
AU  - Höß, C.*
AU  - Treumann, T.*
AU  - Kastner, C.*
AU  - Ulm, K.*
C1  - 22092
C2  - 20747
SP  - 23-33
TI  - Bone metabolism during the perimenopausal transition : A prospective study.
JO  - Maturitas
VL  - 41
PY  - 2002
SN  - 0378-5122
ER  -